MCV4 is a meningococcal conjugate vaccine that protects against four serogroups (A, C, W, and Y) of the bacteria that cause meningococcal disease. This disease, while uncommon, can lead to meningitis (infection of the lining around the brain and spinal cord) and dangerous bloodstream infections that progress rapidly and can be fatal within hours. The CDC recommends MCV4 for all adolescents, with the first dose at age 11 or 12 and a booster at 16.
What MCV4 Protects Against
Meningococcal bacteria come in several serogroups, each designated by a letter. MCV4 targets four of them: A, C, W, and Y. These serogroups are responsible for a significant share of meningococcal cases in the United States and are the dominant strains in many parts of the world, particularly in sub-Saharan Africa and the Middle East.
The infections these bacteria cause fall into two main categories. Meningitis inflames the protective membranes surrounding the brain and spinal cord, causing severe headache, stiff neck, high fever, and sensitivity to light. Bloodstream infection (sometimes called meningococcal septicemia) can cause a distinctive spreading rash, organ failure, and shock. Both forms can kill a previously healthy person in under 24 hours, which is why vaccination before exposure matters so much.
Available Brands in the U.S.
Three MenACWY vaccines are licensed by the FDA:
- Menveo
- Menactra
- MenQuadfi
All three cover the same four serogroups and are considered interchangeable for completing the recommended schedule. Your provider will typically use whichever brand their clinic stocks.
A newer option, called MenABCWY (pentavalent), combines coverage of serogroups A, C, W, and Y with serogroup B in a single vaccine. It can be used when someone needs both MenACWY and MenB protection at the same visit.
Recommended Age and Schedule
For most adolescents, the schedule is straightforward: one dose at age 11 or 12, then a booster dose at age 16. The booster exists because protection fades over time, and the goal is to keep immunity strong through the late teen years, when the risk of meningococcal disease peaks due to close-quarters living situations like college dorms.
If your child misses the 11-to-12 window, the timing adjusts. A first dose given between ages 13 and 15 still calls for a booster between 16 and 18. A first dose given at 16 or older does not need a booster, because the immunity from that single shot covers the highest-risk years.
Who Needs Extra Doses
Certain medical conditions make a person significantly more vulnerable to meningococcal bacteria. People in these groups typically need additional doses and may start the series earlier than age 11. The main risk factors include:
- A missing or nonfunctional spleen, including people with sickle cell disease
- Complement deficiencies, a group of immune system disorders that impair the body’s ability to fight certain bacteria
- HIV
- Medications that block part of the immune system’s complement pathway, such as drugs used for conditions like paroxysmal nocturnal hemoglobinuria
If any of these apply, the dosing schedule is more intensive and may include repeat boosters every few years. Your provider will tailor the plan based on the specific condition.
MCV4 vs. MenB: Different Vaccines for Different Strains
One common source of confusion is the difference between MCV4 and MenB vaccines. They are not interchangeable. MCV4 (MenACWY) covers serogroups A, C, W, and Y. MenB vaccines, sold under the brand names Bexsero and Trumenba, cover only serogroup B. Getting one does not protect you against the strains covered by the other.
MenACWY is routinely recommended for all adolescents. MenB vaccination is typically a shared decision between patients and providers for teens and young adults aged 16 through 23, though it is specifically recommended for people with certain immune conditions. If both are needed at the same visit, the pentavalent MenABCWY vaccine can simplify things into fewer shots.
Side Effects
Most side effects from MCV4 are mild and resolve within one to three days. The most common is soreness, redness, or swelling at the injection site. Some people also experience muscle or joint pain and low-grade fever. These reactions are signs of the immune system responding to the vaccine, not signs of illness.
Severe allergic reactions (anaphylaxis) are extremely rare. The vaccine is not recommended for anyone who has had a severe allergic reaction to a previous dose or to any component of the vaccine. If you’re currently dealing with a moderate or severe illness with or without fever, your provider will likely recommend waiting until you’ve recovered before getting the shot.
Travel Requirements
Certain international destinations require proof of meningococcal vaccination. The most well-known example is Saudi Arabia, which mandates the MenACWY vaccine for all travelers participating in the Hajj or Umrah pilgrimages. This requirement exists for good reason: in 2024 and 2025, cases of meningococcal disease were reported among people who attended these mass gatherings.
If you’re planning travel to sub-Saharan Africa’s “meningitis belt,” which stretches from Senegal to Ethiopia, vaccination is also strongly recommended even where it isn’t legally required. Large outbreaks driven by serogroups A and W occur regularly in that region, particularly during the dry season from December through June.
Why Protection Fades
Like many vaccines, MCV4 doesn’t provide lifelong immunity from a single dose. Antibody levels drop over the years following vaccination, which is precisely why the booster at age 16 is part of the routine schedule. That booster refreshes the immune response during the period when teens are most likely to encounter the bacteria, particularly as they enter college or military service and share living spaces with large numbers of peers. For people with ongoing medical risk factors, repeat boosters every few years keep protection current.